These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1389469)

  • 21. [Carcinostatics on vascular endothelium (author's transl)].
    Ito K
    Yonago Acta Med; 1973 Jul; 17(1):25-33. PubMed ID: 4802152
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting angiogenic metabolism in disease.
    Li X; Carmeliet P
    Science; 2018 Mar; 359(6382):1335-1336. PubMed ID: 29567696
    [No Abstract]   [Full Text] [Related]  

  • 23. Mechanism of the local vascular actions of 1, 1-dimethyl-4-phenylpiperazinium (DMPP), a potent ganglionic stimulant.
    WINBURY MM
    J Physiol; 1959 Jun; 147(1):1-13. PubMed ID: 13673380
    [No Abstract]   [Full Text] [Related]  

  • 24. Optical imaging and tumor angiogenesis.
    Lin PC
    J Cell Biochem; 2003 Oct; 90(3):484-91. PubMed ID: 14523982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies.
    Chen P; Bonaldo P
    Int Rev Cell Mol Biol; 2013; 301():1-35. PubMed ID: 23317816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
    Fischer C; Jonckx B; Mazzone M; Zacchigna S; Loges S; Pattarini L; Chorianopoulos E; Liesenborghs L; Koch M; De Mol M; Autiero M; Wyns S; Plaisance S; Moons L; van Rooijen N; Giacca M; Stassen JM; Dewerchin M; Collen D; Carmeliet P
    Cell; 2007 Nov; 131(3):463-75. PubMed ID: 17981115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
    Lejeune FJ; Rüegg C
    Bull Cancer; 2006 Aug; 93(8):E90-100. PubMed ID: 16935777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
    Iversen AB; Busk M; Horsman MR
    Acta Oncol; 2013 Oct; 52(7):1320-6. PubMed ID: 23988183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma.
    James SE; Salsbury AJ
    Cancer Res; 1974 Apr; 34(4):839-42. PubMed ID: 4814996
    [No Abstract]   [Full Text] [Related]  

  • 31. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments.
    Tanabe K; Zhang Z; Ito T; Hatta H; Nishimoto S
    Org Biomol Chem; 2007 Dec; 5(23):3745-57. PubMed ID: 18004453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.
    Oh DY; Kim TM; Han SW; Shin DY; Lee YG; Lee KW; Kim JH; Kim TY; Jang IJ; Lee JS; Bang YJ
    Cancer Res Treat; 2016 Jan; 48(1):28-36. PubMed ID: 25715767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular changes in tumours after treatment with ICRF 159.
    Le Serve AW; Hellmann K
    Br J Pharmacol; 1971 Oct; 43(2):457P-458P. PubMed ID: 5158233
    [No Abstract]   [Full Text] [Related]  

  • 34. Vascular damaging agents.
    Patterson DM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
    Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
    Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
    [No Abstract]   [Full Text] [Related]  

  • 36. Angiogenesis in brain tumours.
    Jain RK; di Tomaso E; Duda DG; Loeffler JS; Sorensen AG; Batchelor TT
    Nat Rev Neurosci; 2007 Aug; 8(8):610-22. PubMed ID: 17643088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
    Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
    Radiother Oncol; 2006 Feb; 78(2):138-45. PubMed ID: 16455148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular abnormalities of blood vessels as targets in cancer.
    Baluk P; Hashizume H; McDonald DM
    Curr Opin Genet Dev; 2005 Feb; 15(1):102-11. PubMed ID: 15661540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.
    de Vos FY; Willemse PH; de Vries EG; Gietema JA
    Cancer Treat Rev; 2004 Oct; 30(6):495-513. PubMed ID: 15325031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.